RxDoctor Payments Data

Sonya Shah, MD

Ophthalmology · Falls Church, VANPI 1083841886

Payments from drug & device makers

$1,948in general payments, 2019–2025

Across 51 payments — averaging $38.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$672
  • Alcon$278
  • Sight Sciences, Inc.$161
  • Tarsus Pharmaceuticals, Inc.$136
  • Kala Pharmaceuticals, Inc.$125
  • Apellis Pharmaceuticals, Inc.$113
  • plus $464 from 9 others

What the payments were for

  • Food & beverage$1,948100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,948 in reported general payments places this provider in the 65th percentile of 509 ophthalmology providers in Virginia.

See all ophthalmology providers in Virginia

Medicare billing

Part B allowed, 2024
$337,024
Medicare patients
787
Services billed
2,555

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost59$40,953
RestasisCyclosporine22$35,514
VyzultaLatanoprostene Bunod42$31,514
RhopressaNetarsudil Mesylate64$30,551
RocklatanNetarsudil Mesylat/Latanoprost37$28,512
CombiganBrimonidine Tartrate/Timolol53$26,639
XiidraLifitegrast11$22,028
Travoprost84$21,082
Dorzolamide-TimololDorzolamide/Timolol/Pf63$13,468
Brinzolamide63$12,895
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol58$11,299
Brimonidine Tartrate145$10,065
Cyclosporine24$10,022
SimbrinzaBrinzolamide/Brimonidine Tart22$9,631
Alphagan PBrimonidine Tartrate14$8,832

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Restasis, Combigan, Alphagan P$672$111,938148 claims
Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan$56$59,063101 claims
Bausch & Lomb Americas Inc.Vyzulta, Xiidra$23$53,54253 claims
AlconSimbrinza$278$9,63122 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 509 ophthalmology providers in Virginia.

Other ophthalmology in Falls Church

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →